BR112014030404A2 - proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento - Google Patents

proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento

Info

Publication number
BR112014030404A2
BR112014030404A2 BR112014030404A BR112014030404A BR112014030404A2 BR 112014030404 A2 BR112014030404 A2 BR 112014030404A2 BR 112014030404 A BR112014030404 A BR 112014030404A BR 112014030404 A BR112014030404 A BR 112014030404A BR 112014030404 A2 BR112014030404 A2 BR 112014030404A2
Authority
BR
Brazil
Prior art keywords
hgh
fusion protein
growth hormone
treatment
hormone deficiency
Prior art date
Application number
BR112014030404A
Other languages
English (en)
Portuguese (pt)
Inventor
Spink Benjamin
Wang Chia-Wei
Humphriss Eric
M Bright George
L Cleland Jeffrey
Silverman Joshua
Geething Nathan
Schellenberger Volker
P Stemmer Willem
Original Assignee
Amunix Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Operating Inc filed Critical Amunix Operating Inc
Publication of BR112014030404A2 publication Critical patent/BR112014030404A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014030404A 2012-06-05 2013-03-14 proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento BR112014030404A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261689390P 2012-06-05 2012-06-05
US201261663475P 2012-06-22 2012-06-22
US201361763753P 2013-02-12 2013-02-12
PCT/US2013/031673 WO2013184216A1 (en) 2012-06-05 2013-03-14 Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency

Publications (1)

Publication Number Publication Date
BR112014030404A2 true BR112014030404A2 (pt) 2017-06-27

Family

ID=47998551

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014030404A BR112014030404A2 (pt) 2012-06-05 2013-03-14 proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento

Country Status (17)

Country Link
US (2) US20140162949A1 (enExample)
EP (1) EP2858664B1 (enExample)
JP (2) JP2015520188A (enExample)
KR (1) KR20150021072A (enExample)
CN (2) CN104519903A (enExample)
AU (1) AU2013272220A1 (enExample)
BR (1) BR112014030404A2 (enExample)
CA (1) CA2875827A1 (enExample)
DK (1) DK2858664T3 (enExample)
ES (1) ES2733220T3 (enExample)
HK (1) HK1208629A1 (enExample)
IL (1) IL236070A0 (enExample)
MX (1) MX2014014927A (enExample)
NZ (1) NZ702557A (enExample)
PH (1) PH12014502738A1 (enExample)
SG (1) SG11201408152VA (enExample)
WO (1) WO2013184216A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
HK1216617A1 (zh) * 2013-03-11 2016-11-25 Amunix Operating Inc. 用人生长激素类似物治疗小儿生长激素缺乏症
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017136583A1 (en) 2016-02-02 2017-08-10 Versartis, Inc. Growth hormone treatment adherence system
WO2017142331A1 (en) * 2016-02-17 2017-08-24 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
US12233113B2 (en) * 2016-02-17 2025-02-25 Genexine, Inc. Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency
JP2019525931A (ja) * 2016-07-27 2019-09-12 アムニクス ファーマシューティカルズ, インコーポレイテッド ヒト成長ホルモンアナログによる成人成長ホルモン欠乏症の処置
JOP20190019A1 (ar) 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
JP2021507706A (ja) 2017-12-21 2021-02-25 アムニクス ファーマシューティカルズ, インコーポレイテッド 放出セグメントおよびそれを含む結合組成物
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
JP2023545684A (ja) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー,リミテッド ポリペプチドコンジュゲートおよび使用の方法
CN116554343B (zh) * 2022-01-30 2024-07-12 领诺(上海)医药科技有限公司 一种长效重组人生长激素及其应用
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN116003632B (zh) * 2022-12-07 2026-02-24 北京大学 长效缓释型人重组生长激素融合蛋白及其药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898830A (en) 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
SI2393828T1 (sl) * 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
JP5805634B2 (ja) * 2009-06-08 2015-11-04 アムニクス オペレーティング インコーポレイテッド 成長ホルモンポリペプチド並びにその作成及び使用方法

Also Published As

Publication number Publication date
HK1208629A1 (en) 2016-03-11
DK2858664T3 (da) 2019-07-08
WO2013184216A1 (en) 2013-12-12
JP2017125051A (ja) 2017-07-20
EP2858664B1 (en) 2019-05-08
MX2014014927A (es) 2015-05-15
CN104519903A (zh) 2015-04-15
AU2013272220A1 (en) 2015-01-15
US20140162949A1 (en) 2014-06-12
EP2858664A1 (en) 2015-04-15
CA2875827A1 (en) 2013-12-12
US20180051063A1 (en) 2018-02-22
ES2733220T3 (es) 2019-11-28
PH12014502738A1 (en) 2015-02-02
CN107320719A (zh) 2017-11-07
JP2015520188A (ja) 2015-07-16
NZ702557A (en) 2017-06-30
KR20150021072A (ko) 2015-02-27
IL236070A0 (en) 2015-01-29
SG11201408152VA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
MX2016002152A (es) Metodo para aumentar la expresion de proteinas codificadas por arn.
MX372883B (es) Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer.
MY188139A (en) Sodium channel modulators for the treatment of pain
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
MX392752B (es) Terapia de combinacion para tratar cancer.
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
BR112014031088A8 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
EP3590338A3 (en) Medical treatments based on anamorelin
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112018002530A2 (pt) combinações e usos e tratamentos destas
CY1125361T1 (el) Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.